A secondary analysis of the pivotal trial for tricuspid transcatheter edge-to-edge repair indicates that it yields clinically meaningful benefit for select patients with isolated severe tricuspid regurgitation.
One-year results show improvement of severe tricuspid regurgitation and quality-of-life improvements with transcatheter edge-to-edge repair in a select patient population.
When assessing patients with PAH and secondary TR, it’s time to pay more attention to intrinsic right ventricular function, remodeling and hemodynamics. So suggests a new mechanistic study.
The investigational bicaval device promises a potential solution for patients with severe TR and right heart failure who currently have no treatment options.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A study showing good early outcomes after isolated tricuspid valve surgery supports expanding surgical candidacy criteria and operating earlier on patients with functional tricuspid regurgitation.
The jury is still out on whether patients with degenerative mitral regurgitation and less than severe tricuspid regurgitation should undergo tricuspid annuloplasty along with mitral valve surgery.
The study’s resulting risk score predicts mortality outcomes with the aim of providing management guidance. A companion study shows that surgery appears to yield a survival benefit in both primary and secondary TR.